Full Text
EE242 Cost of Managing Brain Metastases in Patients With ALK-Positive Advanced NSCLC With First-Line ALK Tyrosine Kinase Inhibitors (TKIs) in China

Abstract

Authors

B Hu J Xue L Siman J Duan L Luan H Le P Dong H Li

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×